<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973969</url>
  </required_header>
  <id_info>
    <org_study_id>0304-20-ASF</org_study_id>
    <nct_id>NCT04973969</nct_id>
  </id_info>
  <brief_title>Follicular Challenge Test to Predict Response to GnRH Agonist Triggering</brief_title>
  <official_title>Follicular Challenge Test to Predict Response to GnRH Agonist Triggering</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assaf-Harofeh Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assaf-Harofeh Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GnRH agonist triggering is used during ART in order to reduce the risk of OHSS. Some studies&#xD;
      described that in up to 5% of the cycles triggered with GnRH agonist, a lack of respone or&#xD;
      suboptimal response was displayed.&#xD;
&#xD;
      The investigators aim to asses the possibility to predict the respone to ovulation triggering&#xD;
      by the response to decapeptyl in the follicular phase of the same cycle.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will use Decapeptyl on day 2 of menstruation followed by antagonist&#xD;
      protocol.&#xD;
&#xD;
      Hormonal proflie including E2, P, LH, FSH will be measured. LH surge and the rest of the&#xD;
      hormonal profile will be compared to day after ovulation triggering.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The response to GnRH triggering</measure>
    <time_frame>One treatment cycle (each cycle is 28 days) for each participant (up to 28 days).</time_frame>
    <description>LH levels 10-12 hours after decapeptyl trigger, number of mature oocytes</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Infertility, Female</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The participants will recieve decapeptyl 0.2 mg on day 2/3 of the follicular phase.At that day, and at the day after, hormonsl profile will be documented. The hormonal profile of the day after follicular decapeptyl administration will be compared to the hormonal profile to test the predictive value.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Decapeptyl</intervention_name>
    <description>diagnosis of predictio value</description>
    <arm_group_label>study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients that undergo fertility preservation&#xD;
&#xD;
               -  patients planned to freeze embryos due to PGT or surrogacy --patients at high&#xD;
                  risk for OHSS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Poor ovarian response&#xD;
&#xD;
          -  known hypothalamic- pituitary dysfunction&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Infertility patients</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarit Avraham, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asaf Harofe Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarit Avraham, Dr</last_name>
    <phone>00972522371126</phone>
    <email>sarita@shamir.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shamir medical center</name>
      <address>
        <city>Tzrifin</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarit Avraham, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 13, 2021</study_first_submitted>
  <study_first_submitted_qc>July 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>July 21, 2021</last_update_submitted>
  <last_update_submitted_qc>July 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assaf-Harofeh Medical Center</investigator_affiliation>
    <investigator_full_name>Assaf Harofeh MC</investigator_full_name>
    <investigator_title>senior physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

